Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547345 | 0.97 | CYP1A2 (0.48) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL17117380 | 0.96 | GAA (0.47) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL16174758 | 0.92 | CYP1A2 (0.42) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL17791499 | 0.92 | CYP1A2 (0.39) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL22053390 | 0.88 | GAA (0.37) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL19129032 | 0.88 | GAA (0.38) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL17744910 | 0.88 | CYP1A2 (0.43) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL16182384 | 0.87 | CYP1A2 (0.47) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL13267369 | 0.86 | CYP1A2 (0.46) | CYP1A2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL12456428 | 0.86 | CYP1A2 (0.46) | CYP1A2GAAALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | claimed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | claimed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | claimed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | claimed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | claimed |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250230139-A1 | Novel Process and Intermediate for the Preparation of Apalutamide | BDR LIFESCIENCES PRIVATE LIMITED (IN) | 2025-07-17 | — | — | US | disclosed |
| EP-4504715-A1 | NOVEL PROCESS AND INTERMEDIATE FOR THE PREPARATION OF APALUTAMIDE | BDR Lifesciences Private Limited (IN) | 2025-02-12 | — | — | EP | disclosed |
| CN-119301108-A | New process and intermediates for the preparation of apaluramine | BDR生命科学私人有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-09-05 | — | — | US | disclosed |
| EP-4385574-A2 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | The Regents of the University of California (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2013187-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | The Regents of the University of California (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008119015-A2 | SYNTHESIS OF THIOHYDANTOINS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007126765-A2 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127010-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885 |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | CYP1A2 1469/4885GAA 4870/4885ALDH1A1 812/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | CYP1A2 515/4885GAA 4863/4885ALDH1A1 579/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | CYP1A2 2341/4885GAA 4869/4885ALDH1A1 1572/4885 |
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | AR, HRAS, NR5A1 | CYP1A2 2099/4885GAA 4726/4885ALDH1A1 498/4885 |
| US-20250230139-A1 | Novel Process and Intermediate for the Preparation of Apalutamide | PDE8B, PDE8A, PGA5 | CYP1A2 545/4885GAA 69/4885ALDH1A1 1124/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | CYP1A2 668/4885GAA 3990/4885ALDH1A1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.